Healthcare, Pharma & Life Sciences

BAD HOMBURG – – November 02, 2026 -- Fresenius has secured exclusive rights to up to 37 biosimilar candidates under a development agreement with WuXi Biologics. The company calls it the largest development agreement announced in the biosimilars industry to date. The deal could lift Fresenius' portfolio from 29 marketed and pipeline molecules today to as many as 66 over the next decade, addressing more than €370 billion in originator list-price-based sales.

Fresenius keeps full commercial economics and selection control

Fresenius will hold exclusive global commercialization rights, including marketing authorizations, and the full economics of each commercialized product. It will select and advance candidates against three criteria: market attractiveness, development risk and expected returns. Development is expected to run through WuXi Biologics' network across Europe, the United States, China and Singapore.

United States – November 02, 2026 -- Marketplace insurers are proposing a median 15% premium increase for 2027, and Softheon is offering health plans a free 20-minute consultation to find operational bottlenecks before open enrollment (OE) volume peaks.

Carrier exits could send hundreds of thousands of members shopping for coverage

Carrier exits and footprint changes mean hundreds of thousands of Marketplace members could be shopping for new coverage in 2027. Changes across Marketplace and public coverage programs could also bring consumers into OE with more questions about eligibility, subsidies, affordability and where to find coverage.

Bexar County, Texas – November 02, 2026 -- Community First Health Plans (CFHP) generated a 2.2X return on investment in the first year of its Third-Party Payment (TPP) program, and the net profit far exceeded implementation and service fees.

Sponsored members accounted for 87% of CFHP's 2022 enrollments

The Texas-based health plan piloted the hospital-sponsorship model, also called Payvider, in 2022. Sponsored members made up 87% of CFHP's enrollments that year.

Program targets low-income Bexar County residents who visit emergency rooms frequently

CFHP launched the TPP program to close coverage gaps for low-income individuals in Bexar County. It focuses on frequent emergency room visitors.

The pilot enrolled members who met subsidy qualifications but faced affordability barriers. The hospital-sponsorship structure is designed to reduce uninsured rates.

Lombardy – November 02, 2026 -- Bracco held the second Global CEUS Steering Committee in Munich with 14 international experts in contrast-enhanced ultrasound (CEUS), and the group will now meet every year.

The meeting took place alongside the EUROSON School. Participants included specialists from several clinical fields and regions, as well as representatives of Bracco Medical and R&D. The initiative began in China in 2025, when Bracco first assembled CEUS experts across specialties and geographies.

Super-resolution imaging, software and AI top the agenda

Discussions covered super-resolution imaging, new software applications and artificial intelligence. Experts examined possible diagnostic and potentially therapeutic uses of CEUS. They also looked at ways to optimize clinical workflows and at the healthcare and economic considerations that affect adoption.

JOHANNESBURG – November 02, 2026 -- EASE Holdings BV has secured US$9.5 million in additional equity from AAFC Group Inc, lifting its total equity to US$24 million. The medical equipment-as-a-service provider will use the funds to scale operations in South Africa and Ghana.

AAFC Group is a U.S.-based investor in emerging-market asset-backed finance. EASE will combine the new equity with its debt facilities to grow its installed base of advanced, increasingly AI-enhanced medical devices.

EASE targets at least US$20 million of South African installations in 2027

After select initial deployments, EASE expects to place at least US$20 million of new equipment in South Africa next year. It will work with the country's largest banks and leading equipment manufacturers. EASE South Africa plans to expand its board and has appointed Wynand du Plessis of Mindcor-InterSearch to recruit a managing director.

NEW YORK – November 02, 2026 -- Healthcare fintech Superscript is opening its real-time patient pricing platform to any U.S. medical practice or EHR vendor through a new API, covering 3,379 services across 27 specialties.

The platform already serves 1,500 active providers in orthopedics, urgent care and multispecialty groups. It has reached more than 500,000 patients and processed 2.2 million patient billing transactions. athenahealth ranked Superscript its fastest-growing marketplace partner in September.

RALEIGH – November 02, 2026 -- RedHill Biopharma (NASDAQ: RDHL) said two independent in vitro studies confirmed that its Crohn's disease candidate RHB-204 kills Mycobacterium avium subspecies paratuberculosis (MAP) at a level comparable to RHB-104, which posted a 64% efficacy gain in a Phase 3 trial.

Two microbiology centers confirm MAP-killing in culture and phage assays

The studies used long-term intracellular culture and spot and phage assays. One was led by Professor Tim Bull of City St George's University of London. The other was led by Professor Irene Grant of Queen's University Belfast and Dr Hannah Dane, working with Rapid-myco Technologies.

SYDNEY – November 02, 2026 -- Kazia Therapeutics (NASDAQ: KZIA) will present two preclinical abstracts on its lead asset paxalisib at the San Antonio Breast Cancer Symposium (SABCS), held Dec. 8-11, 2026, in San Antonio, Texas.

Poster P4-9-18 challenges the view that dual PI3K/mTOR inhibitors are equivalent

The first poster reports that paxalisib induces durable tumour and immune reprogramming across breast cancer subtypes. Kazia says these effects are not necessarily shared by other dual PI3K/mTOR inhibitors in preclinical models. The company believes the evidence supports a mechanism of action that extends beyond conventional kinase inhibition.

NEW YORK – November 02, 2026 -- Nuvation Bio (NYSE: NUVB) will present four posters on safusidenib, its investigational mutant IDH1 inhibitor, at the Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia on November 12-15, 2026. One poster carries updated long-term Phase 2 J201 results that go beyond the topline data the company announced in July 2026.

Three trial-in-progress posters cover ongoing safusidenib studies

The other three posters give overviews of ongoing safusidenib trials. Nuvation Bio will staff Booth #126 at the meeting and plans to post the materials in the Publications section of its website after the presentations.

CEO David Hung said patients with IDH1-mutant glioma are often diagnosed in their 30s and 40s and need targeted treatments with "durable responses."

BOULDER – November 02, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) granted inducement stock options on 17,250 shares and restricted stock units covering 8,626 shares to two new non-executive employees on October 30, 2026.

Options carry a $38.90 exercise price set at the grant-date close

Each option has an exercise price of $38.90 per share, equal to Edgewise's closing share price on the grant date. The awards were made under the company's 2024 Inducement Equity Incentive Plan.

Options vest over four years, with a one-year cliff

Twenty-five percent of the shares under each option vest on the first anniversary of the employee's start date. The remainder vest in 1/48th monthly installments, subject to continued service.